drugset / Trial / NCT02481609

NAC Trial for Anosmia

NCT02481609

Phase 0 Completed 29 enrolled University of Miami
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evidence that the medication may promote nerve recovery (help nerves work better after they are damaged). Since anosmia involves nerve problems, we believe the nasal spray may help treat anosmia. The medication has been in use for many years for other conditions, without safety problems.

Timeline

Start
2014-07
Primary completion
2017-12-01
Completion
2017-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 200 mg Intranasal

Indications